



November 19, 2009

Dear Valued Client:

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled the enclosed packet of important changes regarding a number of tests we perform. Listed below are the types of changes included in this packet.

Type of Change	Explanation
New Tests	Tests recently added to the NMS Labs test menu
Test Changes	Tests that have had changes to their method/CPT code, units of measurement, scope of analysis or specimen requirements
Discontinued Tests	Tests being discontinued with alternate testing suggestions

Please be advised all changes listed in this packet will go into effect on **March 1, 2010**. Please use this packet of information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this packet, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

Sincerely,

NMS Labs

Database Changes - Summary

Test Code	Test Name	New Test	Method/ CPT code	Units	Scope	Specimen Reqs	Stability	Discontinued	Reference Comment	Misc.
0158SP	Acyclovir, Serum/Plasma		•			•				
0158U	Acyclovir, Urine		•				•			
0165B	Albuterol, Blood						•			
0165SP	Albuterol, Serum/Plasma						•			
0165U	Albuterol, Urine							•		
1284U	Citalopram Screen, Urine (CSA)							•		
1840U	Drug Screen, Urine (CSA)							•		
1862ME	Drug Screen 62, Meconium (CSA)							•		
2076SP	Famciclovir as Metabolite, Serum/Plasma		•			•	•			
2112B	Tamoxifen, Blood							•		
2112SP	Tamoxifen, Serum/Plasma							•		
2112U	Tamoxifen, Urine							•		
2130U	Fluvoxamine Screen, Urine (CSA)							•		
2154SP	Ganciclovir, Serum/Plasma		•			•	•			
2154U	Ganciclovir, Urine		•				•			
2661SP	Metals/Metalloids Panel 1, Serum/Plasma						•			
2663SP	Metals/Metalloids Panel 3, Serum/Plasma						•			
2670SP	Mercury, Serum/Plasma						•			
2670UH	Mercury, 24 Hour Urine						•			
2676U	Mercury, Urine (CSA)						•			
2693SP	Metals/Metalloids Acute Poisoning Panel, Serum/Plasma						•			
2693U	Metals/Metalloids Acute Poisoning Panel, Urine						•			
2695B	Metaproterenol, Blood							•		
2695SP	Metaproterenol, Serum/Plasma							•		
2695U	Metaproterenol, Urine							•		
3230B	Symbyax, Blood	•								
3230FL	Symbyax, Fluid	•								
3230SP	Symbyax, Serum/Plasma	•								
3230TI	Symbyax, Tissue	•								
3230U	Symbyax, Urine	•								
3381SP	Penciclovir, Serum/Plasma		•				•			
3704B	Phenylephrine, Blood							•		
3704SP	Phenylephrine, Serum/Plasma						•			
4112B	Ritodrine, Blood							•		
4112SP	Ritodrine, Serum/Plasma							•		
4112U	Ritodrine, Urine							•		
4127SP	Suboxone - Free, Serum/Plasma	•								
4206B	Sodium - Total, Blood					•				
4206FL	Sodium - Total, Fluid					•				
4206R	Sodium - Total, RBCs					•				
4206SP	Sodium - Total, Serum/Plasma					•				
4206U	Sodium - Total, Urine					•				
4311B	Tamoxifen and Metabolites, Blood	•								
4311SP	Tamoxifen and Metabolites, Serum/Plasma	•								
4326B	Terbutaline, Blood							•		

NMS Labs

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

Database Changes - Summary

Test Code	Test Name	New Test	Method/ CPT code	Units	Scope	Specimen Reqs	Stability	Discontinued	Reference Comment	Misc.
4326SP	Terbutaline, Serum/Plasma					•	•			
4645FL	1,1,1-Trichloroethane, Fluid (CSA)							•		
4766SP	Valacyclovir as Metabolite, Serum/Plasma		•			•				
8038SP	Drug Screen, Serum/Plasma (CSA)							•		

NMS Labs

3701 Welsh Road, Willow Grove, PA 19090

800-522-6671

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4127SP	Suboxone - Free, Serum/Plasma			
	Scope of Analysis: Buprenorphine - Free	0.5	ng/mL	LC-MS/MS (83925)
	Reference Comment: Suboxone® is available as sublingual tablets containing Buprenorphine (BUP) and Naloxone (NAL) in a 4:1 ratio. There are two dosage forms: 2 mg BUP: 0.5 mg NAL and 8 mg BUP: 2 mg NAL. Following a single dose of the Suboxone® mean maximum plasma Buprenorphine concentrations (+/- 1 S.D.) were: 4 mg BUP: 1 mg NAL: 2.33 +/- 0.80 ng/mL 8 mg BUP: 2 mg NAL: 3.53 +/- 1.16 ng/mL 16 mg BUP: 4 mg NAL: 5.83 +/- 2.09 ng/mL 24 mg BUP: 6 mg NAL: 6.44 +/- 2.10 ng/mL			
	Scope of Analysis: Norbuprenorphine - Free	0.5	ng/mL	
	Reference Comment: Norbuprenorphine is the primary metabolite of BUP. Following a single dose of Suboxone® (a 4:1 ratio of Buprenorphine and Naloxone) mean maximum plasma Norbuprenorphine concentrations (+/- 1 S.D.) were: 4 mg BUP: 1 mg NAL: 0.83 +/- 0.27 ng/mL 8 mg BUP: 2 mg NAL: 1.48 +/- 0.56 ng/mL 16 mg BUP: 4 mg NAL: 3.50 +/- 1.39 ng/mL			
	Scope of Analysis: Naloxone - Free	0.5	ng/mL	LC-MS/MS (83925)
	Reference Comment: Suboxone® is available as sublingual tablets containing Buprenorphine (BUP) and Naloxone (NAL) in a 4:1 ratio. There are two dosage forms: 2 mg BUP: 0.5 mg NAL and 8 mg BUP: 2 mg NAL. Following a single dose of the Suboxone® mean maximum plasma naloxone concentrations (+/- 1 S.D.) were: 4 mg BUP: 1 mg NAL: 0.12 +/- 0.05 ng/mL 8 mg BUP: 2 mg NAL: 0.25 +/- 0.09 ng/mL 16 mg BUP: 4 mg NAL: 0.45 +/- 0.27 ng/mL 24 mg BUP: 6 mg NAL: 0.47 +/- 0.26 ng/mL			
	Specimen Requirements: Specimen Requirements: 2 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).			
	Stability: Room Temperature: 7 day(s) Refrigerated: 10 day(s) Frozen (-20 °C): 30 day(s)			

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3230B	Symbyax, Blood			
	Scope of Analysis: Olanzapine	3	ng/mL	GC (82491)
	Reference Comment: Olanzapine (Zyprexa®) is administered orally (5 to 20 mg daily) or by intramuscular injection (2.5 to 10 mg) for the relief of symptoms. Olanzapine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Plasma concentrations in patients receiving 10, 15 or 20 mg of olanzapine daily chronically were reported to average 9.3, 19 and 26 ng/mL respectively. The whole blood to plasma ratio for olanzapine is unknown.			
	Scope of Analysis: Fluoxetine	20	ng/mL	GC/MS (82542)
	Reference Comment: Chronic daily doses of 40 mg of fluoxetine (Prozac®) for 1 month produced reported plasma concentrations ranging from 91 - 302 ng/mL for fluoxetine and 72 - 258 ng/mL for norfluoxetine, its active metabolite. Fluoxetine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Toxicity with fluoxetine is not routinely observed at combined concentrations of fluoxetine and norfluoxetine below 2,000 ng/mL. The whole blood to plasma ratio for fluoxetine is 1.0			
	Scope of Analysis: Norfluoxetine	20	ng/mL	
	Reference Comment: Norfluoxetine is the major active metabolite of fluoxetine (Prozac®), and fluoxetine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Chronic daily doses of 40 mg of fluoxetine for 1 month produced reported plasma concentrations ranging from 91 - 302 ng/mL for fluoxetine and 72 - 258 ng/mL for norfluoxetine. The whole blood to plasma ratio for norfluoxetine is unknown.			
	Specimen Requirements: Specimen Requirements: 9 mL Blood Transport Temperature: Frozen Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature. Received Refrigerated.			
	Stability: Room Temperature: Not Stable Refrigerated: 2 day(s) Frozen (-20 °C): 14 day(s)			

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3230FL	Symbyax, Fluid			
	Scope of Analysis: Olanzapine	15	ng/mL	GC (82491)
	Scope of Analysis: Fluoxetine	10	ng/mL	GC/MS (82542)
	Scope of Analysis: Norfluoxetine	10	ng/mL	
	Reference Comment: No reference data available.			
	Specimen Requirements: Specimen Requirements: 5 mL Fluid Transport Temperature: Frozen Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: None			
	Stability: Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined			
3230SP	Symbyax, Serum/Plasma			
	Scope of Analysis: Olanzapine	3	ng/mL	GC (82491)
	Reference Comment: Olanzapine (Zyprexa®) is administered orally (5 to 20 mg daily) or by intramuscular injection (2.5 to 10 mg) for the relief of symptoms. Olanzapine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Plasma concentrations in patients receiving 10, 15 or 20 mg of olanzapine daily chronically were reported to average 9.3, 19 and 26 ng/mL respectively.			
	Scope of Analysis: Fluoxetine	10	ng/mL	GC/MS (82542)
	Reference Comment: Chronic daily doses of 40 mg of fluoxetine (Prozac®) for 1 month produced reported plasma concentrations ranging from 91 - 302 ng/mL for fluoxetine and 72 - 258 ng/mL for norfluoxetine, its active metabolite. Fluoxetine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Toxicity with fluoxetine is not routinely observed at combined concentrations of fluoxetine and norfluoxetine below 2,000 ng/mL.			
	Scope of Analysis: Norfluoxetine	10	ng/mL	

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
	<p>Reference Comment: Norfluoxetine is the major active metabolite of fluoxetine (Prozac®), and fluoxetine is also a component of Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Chronic daily doses of 40 mg of fluoxetine for 1 month produced reported plasma concentrations ranging from 91 - 302 ng/mL for fluoxetine and 72 - 258 ng/mL for norfluoxetine.</p> <p>Specimen Requirements: Specimen Requirements: 5 mL Serum or Plasma Transport Temperature: Frozen Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Received Room Temperature. Received Refrigerated. Polymer gel separation tube (SST or PST).</p> <p>Stability: Room Temperature: Not Stable Refrigerated: 2 day(s) Frozen (-20 °C): 14 day(s)</p>			
3230TI	<p>Symbyax, Tissue</p> <p>Scope of Analysis: Olanzapine Scope of Analysis: Fluoxetine Scope of Analysis: Norfluoxetine Reference Comment: No reference data available.</p> <p>Specimen Requirements: Specimen Requirements: 10 g Tissue Transport Temperature: Frozen Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: None</p> <p>Stability: Room Temperature: Undetermined Refrigerated: Undetermined Frozen (-20 °C): Undetermined</p>	<p>15 50 50</p>	<p>ng/g ng/g ng/g</p>	<p>GC (80103, 82491) GC/MS (80103, 82542)</p>

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
3230U	Symbyax, Urine			
	Scope of Analysis: Fluoxetine	20	ng/mL	GC/MS (82542)
	Reference Comment:	<p>Fluoxetine (Prozac®) is a serotonin-selective reuptake inhibitor (SSRI) used to help control major depressive disorders. Fluoxetine is also included in Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). Norfluoxetine, the major metabolite of fluoxetine, is active pharmacologically. There are no available reference data for fluoxetine in urine.</p> <p>Symbyax® contains both olanzapine and fluoxetine; however, olanzapine was not measured in urine because of the relatively small amount of unchanged drug excreted by the kidney.</p>		
	Scope of Analysis: Norfluoxetine	20	ng/mL	
	Reference Comment:	<p>Norfluoxetine is the major active metabolite of fluoxetine (Prozac®), a serotonin-selective reuptake inhibitor (SSRI) used to help control major depressive disorders. Fluoxetine is a serotonin-selective reuptake inhibitor (SSRI) used to help control major depressive disorders. Fluoxetine is also included in Symbyax®, a combination therapy for treatment-resistant depression that contains fluoxetine (25 or 50 mg) and olanzapine (3, 6 or 12 mg). There are no available reference data for norfluoxetine in urine.</p> <p>Symbyax® contains both olanzapine and fluoxetine; however, olanzapine was not measured in urine because of the relatively small amount of unchanged drug excreted by the kidney.</p>		
	Specimen Requirements:	<p>Specimen Requirements: 2 mL Urine Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: None</p>		
	Stability:	<p>Room Temperature: 7 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 18 month(s)</p>		

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4311B	Tamoxifen and Metabolites, Blood			
	Scope of Analysis: Tamoxifen	1	ng/mL	LC-MS/MS (82542)
	Reference Comment: Tamoxifen undergoes demethylation to N-desmethyltamoxifen and tamoxifen and N-desmethyltamoxifen are hydroxylated to 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen), respectively. Tamoxifen is a prodrug; the pharmacological effects are mediated through its hydroxylated metabolites. A dose-concentration relationship has been identified for tamoxifen. In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma tamoxifen concentrations were: 1 mg/day = 7.5 (2.9 - 120.9) ng/mL 5 mg/day = 25.2 (1.9 - 180.9) ng/mL 20 mg/day = 83.6 (8.7 - 134.4) ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.			
	Scope of Analysis: 4-Hydroxy-Tamoxifen	1	ng/mL	
	Reference Comment: A dose-concentration relationship has been identified for 4-hydroxytamoxifen, an active tamoxifen metabolite. In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma 4-hydroxytamoxifen concentrations were: 1 mg/day = 0.6 (0.4 - 6.0) ng/mL 5 mg/day = 1.3 (0.4 - 5.9) ng/mL 20 mg/day = 3.1 (0.4 - 7.3) ng/mL Hydroxylation of tamoxifen to 4-hydroxytamoxifen is catalyzed by CYP2D6 and genetic polymorphisms which result in low CYP2D6 activity (poor metabolizers) or co-administration of drugs which inhibit CYP2D6 can greatly reduce plasma concentrations of 4-hydroxytamoxifen reducing the overall efficacy of tamoxifen. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.			
	Scope of Analysis: N-desmethyltamoxifen	1	ng/mL	

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
	<p>Reference Comment: A dose-concentration relationship has been identified for N-desmethyltamoxifen, an inactive tamoxifen metabolite.</p> <p>In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma N-desmethyltamoxifen concentrations were: 1 mg/day = 9.9 (1.3 - 135) ng/mL 5 mg/day = 36.2 (3.6 - 282.2) ng/mL 20 mg/day = 112.3 (14.3 - 211.6) ng/mL The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte</p>			
	<p>Scope of Analysis: Endoxifen</p> <p>Reference Comment: Hydroxylation of N-desmethyltamoxifen to endoxifen, an active tamoxifen metabolite, is catalyzed by CYP2D6 and genetic polymorphisms which result in low CYP2D6 activity (poor metabolizers) or co-administration of drugs which inhibit CYP2D6 can greatly reduce plasma concentrations of endoxifen reducing the overall efficacy of tamoxifen.</p> <p>Women receiving 30 mg tamoxifen/day for 10 - 112 (average = 42) days had a mean (range) endoxifen plasma concentration of 8.6 +/- 7.0 (3.0 - 28.0) ng/mL.</p> <p>In one study, patients taking a CYP2D6 inhibitor along with tamoxifen had mean plasma endoxifen concentrations of 14.8 +/- 10.6 as compared to patients taking only tamoxifen (mean plasma concentration = 26.7 +/- 15.4 ng/mL). In comparison, CYP2D6 poor metabolizers had mean plasma endoxifen concentrations of 7.2 +/- 2.3 ng/mL. The ratio of whole blood concentration to serum or plasma concentration is unknown for this analyte.</p>	1	ng/mL	
	<p>Specimen Requirements: Specimen Requirements: 1 mL Blood Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.</p> <p>Stability: Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)</p>			

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
4311SP	Tamoxifen and Metabolites, Serum/Plasma			
	Scope of Analysis: Tamoxifen	1	ng/mL	LC-MS/MS (82542)
	Reference Comment: Tamoxifen undergoes demethylation to N-desmethyltamoxifen and tamoxifen and N-desmethyltamoxifen are hydroxylated to 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen), respectively. Tamoxifen is a prodrug; the pharmacological effects are mediated through its hydroxylated metabolites. A dose-concentration relationship has been identified for tamoxifen. In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma tamoxifen concentrations were: 1 mg/day = 7.5 (2.9 - 120.9) ng/mL 5 mg/day = 25.2 (1.9 - 180.9) ng/mL 20 mg/day = 83.6 (8.7 - 134.4) ng/mL.			
	Scope of Analysis: 4-Hydroxy-Tamoxifen	1	ng/mL	
	Reference Comment: A dose-concentration relationship has been identified for 4-hydroxytamoxifen, an active tamoxifen metabolite. In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma 4-hydroxytamoxifen concentrations were: 1 mg/day = 0.6 (0.4 - 6.0) ng/mL 5 mg/day = 1.3 (0.4 - 5.9) ng/mL 20 mg/day = 3.1 (0.4 - 7.3) ng/mL Hydroxylation of tamoxifen to 4-hydroxytamoxifen is catalyzed by CYP2D6 and genetic polymorphisms which result in low CYP2D6 activity (poor metabolizers) or co-administration of drugs which inhibit CYP2D6 can greatly reduce plasma concentrations of 4-hydroxytamoxifen reducing the overall efficacy of tamoxifen.			
	Scope of Analysis: N-desmethyltamoxifen	1	ng/mL	
	Reference Comment: A dose-concentration relationship has been identified for N-desmethyltamoxifen, an inactive tamoxifen metabolite. In patients receiving 1, 5, or 20 mg/day tamoxifen for 28 days, mean (range) plasma N-desmethyltamoxifen concentrations were: 1 mg/day = 9.9 (1.3 - 135) ng/mL 5 mg/day = 36.2 (3.6 - 282.2) ng/mL 20 mg/day = 112.3 (14.3 - 211.6) ng/mL			

NEW TESTS

Test Code	Test Name	Reporting Limit	Units	Method / CPT Code
	<p>Scope of Analysis: Endoxifen</p> <p>Reference Comment: Hydroxylation of N-desmethyltamoxifen to endoxifen, an active tamoxifen metabolite, is catalyzed by CYP2D6 and genetic polymorphisms which result in low CYP2D6 activity (poor metabolizers) or co-administration of drugs which inhibit CYP2D6 can greatly reduce plasma concentrations of endoxifen reducing the overall efficacy of tamoxifen.</p> <p>Women receiving 30 mg tamoxifen/day for 10 - 112 (average = 42) days had a mean (range) endoxifen plasma concentration of 8.6 +/- 7.0 (3.0 - 28.0) ng/mL.</p> <p>In one study, patients taking a CYP2D6 inhibitor along with tamoxifen had mean plasma endoxifen concentrations of 14.8 +/- 10.6 as compared to patients taking only tamoxifen (mean plasma concentration = 26.7 +/- 15.4 ng/mL). In comparison, CYP2D6 poor metabolizers had mean plasma endoxifen concentrations of 7.2 +/- 2.3 ng/mL.</p> <p>Specimen Requirements: Specimen Requirements: 1 mL Blood Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: Received Room Temperature.</p> <p>Stability: Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)</p>	1	ng/mL	

Updates effective:
March 1, 2010

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com



TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
0158SP	Acyclovir, Serum/Plasma		
	Scope: Acyclovir	mcg/mL	LC-MS/MS (83789)
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Requested volume was decreased.		
0158U	Acyclovir, Urine		
	Scope: Acyclovir	mcg/mL	LC-MS/MS (83789)
	Specimen Requirements: Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: None Rejection Criteria: None Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Stability was changed.		
0165B	Albuterol, Blood		
	Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.		
0165SP	Albuterol, Serum/Plasma		
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.		

Updates effective:
March 1, 2010

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com



TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
2076SP	Famciclovir as Metabolite, Serum/Plasma		
	Scope: Penciclovir	mcg/mL	LC-MS/MS (83789)
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Stability was changed. Requested volume was decreased.		
2154SP	Ganciclovir, Serum/Plasma		
	Scope: Ganciclovir	mcg/mL	LC-MS/MS (83789)
	Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).		
	Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Stability was changed. Requested volume was decreased.		

Updates effective:
March 1, 2010

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com



TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
2154U	Ganciclovir, Urine Scope: Ganciclovir Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)	mcg/mL	LC-MS/MS (83789)
Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Stability was changed.			
2670SP	Mercury, Serum/Plasma Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.			
2670UH	Mercury, 24 Hour Urine Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.			
2676U	Mercury, Urine (CSA) Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.			
2693SP	Metals/Metalloids Acute Poisoning Panel, Serum/Plasma Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.			
2693U	Metals/Metalloids Acute Poisoning Panel, Urine Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 7 day(s)		
Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.			

Updates effective:
March 1, 2010

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com



TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
2661SP	Metals/Metalloids Panel 1, Serum/Plasma Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.		
2663SP	Metals/Metalloids Panel 3, Serum/Plasma Stability: Room Temperature: 14 day(s) Refrigerated: 14 day(s) Frozen (-20 °C): 14 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.		
3381SP	Penciclovir, Serum/Plasma Scope: Penciclovir Stability: Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)	mcg/mL	LC-MS/MS (83789)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Stability was changed.		
3704SP	Phenylephrine, Serum/Plasma Stability: Room Temperature: 1 day(s) Refrigerated: 2 day(s) Frozen (-20 °C): 8 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed.		
4766SP	Valacyclovir as Metabolite, Serum/Plasma Scope: Acyclovir Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST).	mcg/mL	LC-MS/MS (83789)
	Summary of Updates: For Quality Improvement purposes the following updates were made. Method was changed. Requested volume was decreased.		

TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
4206B	Sodium - Total, Blood Specimen Requirements: Specimen Requirements: 1 mL Blood Transport Temperature: Refrigerated Specimen Container: Light Green top tube (Lithium Heparin) Light Protection: Not Required Special Handling: Submit in container with a non-Sodium based preservative/anticoagulant. Tubes containing Sodium based preservatives/anticoagulants are not acceptable. Rejection Criteria: Gray top tube (Sodium Fluoride / Potassium Oxalate). Green top tube (Sodium Heparin). Lavender top tube (EDTA). Light Blue top tube (Sodium Citrate). Royal Blue top tube (Trace metal-free; EDTA). Royal Blue top tube (Trace metal-free; Sodium Heparin). Tan top tube - glass (Sodium Heparin). Tan top tube - plastic (K2EDTA). Yellow top tube (ACD - Acid Citrate Dextrose). Yellow top tube (SPS - Sodium Polyanethol Sulfonate).		
	Summary of Updates:		For Quality Improvement purposes the following updates were made. Requested volume was decreased.
4206FL	Sodium - Total, Fluid Specimen Requirements: Specimen Requirements: 1 mL Fluid Transport Temperature: Refrigerated Specimen Container: Plastic container (Acid washed or Trace metal-free) Light Protection: Not Required Special Handling: None Rejection Criteria: None		
	Summary of Updates:		For Quality Improvement purposes the following updates were made. Requested volume was decreased.
4206R	Sodium - Total, RBCs Specimen Requirements: Specimen Requirements: 1 mL RBCs Transport Temperature: Refrigerated Specimen Container: Light Green top tube (Lithium Heparin) Light Protection: Not Required Special Handling: Submit in container with a non-Sodium based preservative/anticoagulant. Tubes containing Sodium based preservatives/anticoagulants are not acceptable. Centrifuge and separate RBCs into an acid washed plastic screw capped vial within two hours of collection. Rejection Criteria: Received Frozen. Gray top tube (Sodium Fluoride / Potassium Oxalate). Green top tube (Sodium Heparin). Lavender top tube (EDTA). Light Blue top tube (Sodium Citrate). Royal Blue top tube (Trace metal-free; EDTA). Royal Blue top tube (Trace metal-free; Sodium Heparin). Tan top tube - glass (Sodium Heparin). Tan top tube - plastic (K2EDTA). Yellow top tube (ACD - Acid Citrate Dextrose). Yellow top tube (SPS - Sodium Polyanethol Sulfonate).		
	Summary of Updates:		For Quality Improvement purposes the following updates were made. Requested volume was decreased.

TEST UPDATES

Method/CPT Code*, Units of Measurement, Scope of Analysis: and Specimen Requirements

Test Code	Test Name	Units	Method / CPT Code
4206SP	Sodium - Total, Serum/Plasma Specimen Requirements: Specimen Requirements: 1 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: Polymer gel separation tube (SST or PST), Red top tube (no additive) Light Protection: Not Required Special Handling: Hemolyzed Specimens are unsuitable for analysis. Submit in container with a non-Sodium based preservative/anticoagulant. Tubes containing Sodium based preservatives/anticoagulants are not acceptable. Promptly centrifuge and separate Serum or Plasma into an acid washed plastic screw capped vial using approved guidelines. Rejection Criteria: Gray top tube (Sodium Fluoride / Potassium Oxalate). Green top tube (Sodium Heparin). Lavender top tube (EDTA). Light Blue top tube (Sodium Citrate). Royal Blue top tube (Trace metal-free; EDTA). Tan top tube - glass (Sodium Heparin). Tan top tube - plastic (K2EDTA). Yellow top tube (ACD - Acid Citrate Dextrose). Yellow top tube (SPS - Sodium Polyanechol Sulfonate).		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Requested volume was decreased.		
4206U	Sodium - Total, Urine Specimen Requirements: Specimen Requirements: 1 mL Urine Transport Temperature: Refrigerated Specimen Container: Plastic container (Acid washed or Trace metal-free) Light Protection: Not Required Special Handling: Avoid exposure to gadolinium-based contrast media for 48 hours prior to sample collection. Rejection Criteria: None		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Requested volume was decreased.		
4326SP	Terbutaline, Serum/Plasma Specimen Requirements: Specimen Requirements: 8 mL Serum or Plasma Transport Temperature: Refrigerated Specimen Container: NMS Labs has no experimental or literature-based data regarding the choice of specific specimen collection containers for this test. Light Protection: Not Required Special Handling: Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines. Rejection Criteria: Polymer gel separation tube (SST or PST). Stability: Room Temperature: 14 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)		
	Summary of Updates: For Quality Improvement purposes the following updates were made. Stability was changed. Requested volume was increased.		

Updates effective:
March 1, 2010

NMS Labs
3701 Welsh Road, Willow Grove, PA 19090
800-522-6671
nms@nmslabs.com



DISCONTINUED TESTS

Test Code	Test Name	Alternative Test
4645FL	1,1,1-Trichloroethane, Fluid (CSA)	No alternate test available
0165U	Albuterol, Urine	0165SP Albuterol, Serum/Plasma
1284U	Citalopram Screen, Urine (CSA)	1272U Citalopram, Urine
1862ME	Drug Screen 62, Meconium (CSA)	1864ME Drug Screen I, Meconium
8038SP	Drug Screen, Serum/Plasma (CSA)	No alternate test available
1840U	Drug Screen, Urine (CSA)	No alternate test available
2130U	Fluvoxamine Screen, Urine (CSA)	2124U Fluvoxamine, Urine
2695B	Metaproterenol, Blood	No alternate test available
2695SP	Metaproterenol, Serum/Plasma	No alternate test available
2695U	Metaproterenol, Urine	No alternate test available
3704B	Phenylephrine, Blood	3704SP Phenylephrine, Serum/Plasma
4112B	Ritodrine, Blood	No alternate test available
4112SP	Ritodrine, Serum/Plasma	No alternate test available
4112U	Ritodrine, Urine	No alternate test available
2112B	Tamoxifen, Blood	4311B Tamoxifen and Metabolites, Blood
2112SP	Tamoxifen, Serum/Plasma	4311SP Tamoxifen and Metabolites, Serum/Plasma
2112U	Tamoxifen, Urine	No alternate test available
4326B	Terbutaline, Blood	4326SP Terbutaline, Serum/Plasma 7734SA Special Request